Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
In this prospective phase II observational study, we plan to assess the efficacy and
tolerability of caspofungin based combined anti-fungal therapy for proven or probable IFI in
a group of patients received allo-HSCT transplantation with high risk of IFI: HLA matched
unrelated donor or mismatched donor conditioning with ATG containing regimen or present
III-IV aGVHD or extensive GVHD undergoing high-dose steroid treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Treatments:
Amphotericin B Antifungal Agents Caspofungin Echinocandins Liposomal amphotericin B Miconazole Voriconazole